Compare WYETH LTD with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs GLENMARK PHARMA - Comparison Results

WYETH LTD     Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD GLENMARK PHARMA WYETH LTD/
GLENMARK PHARMA
 
P/E (TTM) x 27.7 10.9 253.8% View Chart
P/BV x 5.3 1.4 382.7% View Chart
Dividend Yield % 1.3 0.7 176.9%  

Financials

 WYETH LTD   GLENMARK PHARMA
EQUITY SHARE DATA
    WYETH LTD
Mar-13
GLENMARK PHARMA
Mar-19
WYETH LTD/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,044712 146.8%   
Low Rs818484 169.1%   
Sales per share (Unadj.) Rs298.6349.6 85.4%  
Earnings per share (Unadj.) Rs57.232.8 174.6%  
Cash flow per share (Unadj.) Rs58.444.3 131.8%  
Dividends per share (Unadj.) Rs17.002.00 850.0%  
Dividend yield (eoy) %1.80.3 545.5%  
Book value per share (Unadj.) Rs249.5198.6 125.6%  
Shares outstanding (eoy) m22.72282.17 8.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.11.7 182.5%   
Avg P/E ratio x16.318.2 89.2%  
P/CF ratio (eoy) x15.913.5 118.3%  
Price / Book Value ratio x3.73.0 124.1%  
Dividend payout %29.76.1 486.8%   
Avg Mkt Cap Rs m21,157168,625 12.5%   
No. of employees `0000.512.0 4.1%   
Total wages/salary Rs m40020,561 1.9%   
Avg. sales/employee Rs Th13,787.48,196.0 168.2%   
Avg. wages/employee Rs Th813.01,708.1 47.6%   
Avg. net profit/employee Rs Th2,643.3768.5 344.0%   
INCOME DATA
Net Sales Rs m6,78398,655 6.9%  
Other income Rs m3532,081 16.9%   
Total revenues Rs m7,136100,736 7.1%   
Gross profit Rs m1,61715,858 10.2%  
Depreciation Rs m273,259 0.8%   
Interest Rs m63,346 0.2%   
Profit before tax Rs m1,93811,335 17.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-51,672 -0.3%   
Tax Rs m6323,756 16.8%   
Profit after tax Rs m1,3019,250 14.1%  
Gross profit margin %23.816.1 148.3%  
Effective tax rate %32.633.1 98.4%   
Net profit margin %19.29.4 204.5%  
BALANCE SHEET DATA
Current assets Rs m6,98466,968 10.4%   
Current liabilities Rs m2,05640,211 5.1%   
Net working cap to sales %72.627.1 267.9%  
Current ratio x3.41.7 204.0%  
Inventory Days Days9983 119.1%  
Debtors Days Days2481 29.5%  
Net fixed assets Rs m24433,322 0.7%   
Share capital Rs m227282 80.5%   
"Free" reserves Rs m5,44155,770 9.8%   
Net worth Rs m5,66856,052 10.1%   
Long term debt Rs m2535,738 0.1%   
Total assets Rs m7,901132,888 5.9%  
Interest coverage x353.34.4 8,052.9%   
Debt to equity ratio x00.6 0.7%  
Sales to assets ratio x0.90.7 115.6%   
Return on assets %16.59.5 174.4%  
Return on equity %22.916.5 139.0%  
Return on capital %34.017.8 191.1%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1562,998 0.0%   
Fx outflow Rs m2,67722,859 11.7%   
Net fx Rs m-2,66240,140 -6.6%   
CASH FLOW
From Operations Rs m92313,242 7.0%  
From Investments Rs m317-6,990 -4.5%  
From Financial Activity Rs m-481-7,387 6.5%  
Net Cashflow Rs m759-2,971 -25.6%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 6.9 163.8%  
FIIs % 7.2 34.4 20.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 10.5 289.5%  
Shareholders   21,978 56,727 38.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  PROCTER & GAMBLE HEALTH  GSK PHARMA  

Compare WYETH LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

How to Trade this Market Crash(Podcast)

India's #1 trader, Vijay Bhambwani, decodes the crash...and reveals hidden opportunities one could profit from.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Multibaggers of the Next Decade(The 5 Minute Wrapup)

Feb 26, 2020

The one key ingredient to be seen amongst top multibaggers of the next decade.

The Next Few Days Are Crucial for Smallcap Investors - And 3 Must-Buy Stocks(Profit Hunter)

Feb 19, 2020

While I have been writing about the rebound in smallcaps for quite some time now... I have shied from the question - When exactly is the smallcap rebound happening. Well, the answer is now.

The Top 8 Trading Mistakes You Should Avoid(Fast Profits Daily)

Feb 18, 2020

Avoid these mistakes and your trading will turn much more profitable.

Corona Virus Could Trigger a Rally in this Stock(Profit Hunter)

Feb 20, 2020

A company which benefits from crude oil and coronavirus - if you would like to know more about it read this.

Why I Expect the Coronavirus to Benefit My Latest Trade Recommendation(Fast Profits Daily)

Feb 19, 2020

This is how my latest trade recommendation will benefit from the Coronavirus scare.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get our special report, Secret to Increasing Your Trading Profits Today Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - DR. DATSONS LABS COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS